Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP17-302 adalimumab biosimilar vs US-licensed Humira in rheumatoid arthritis
2015-003433-10Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Hexal AG. Primary endpoint: Change from baseline in DAS28-CRP at Week 12. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-003433-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003433-10.